Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets
MedComm, Volume 7, Issue 2, February 2026.This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen +5 more
wiley +1 more source
Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial [PDF]
, 2023 Chung‐Han Lee +23 more
openalex +1 more source
Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
Statistics in Medicine, Volume 45, Issue 3-5, February 2026.ABSTRACT Phase 2 clinical trials typically rely on a single primary endpoint, yet in many settings, treatment efficacy must be demonstrated across multiple co‐primary endpoints. Such settings require intersection‐union hypothesis testing, in which the global null hypothesis is rejected only when all individual component hypotheses are rejected ...
Hyejung Jung +3 more
wiley +1 more source
Aging Cell, Volume 25, Issue 2, February 2026.Using in vitro DNA damage assays in human T cells, ex vivo profiling of aged immune subsets and a small placebo‐controlled in vivo study, authors show that low‐dose rapamycin, a potent life‐extending mTOR inhibitor, enhances resilience against DNA damage in the human immune system.
Loren Kell +8 more
wiley +1 more source
Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients: Flawed Model or a Model for Future Use? [PDF]
, 2005 Randall C. Starling, John M. Kovarik
openalex +1 more source
Clinical Transplantation, Volume 40, Issue 2, February 2026.ABSTRACT Background Non‐melanoma skin cancer (NMSC) is a frequent long‐term complication in transplant recipients, mainly due to chronic immunosuppression. Its incidence varies by transplant type and regimen, but existing evidence is often fragmented.
Corrado Zengarini +7 more
wiley +1 more source
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM) [PDF]
, 2015 Sai‐Hong Ignatius Ou +7 more
openalex +1 more source
Early use of everolimus improved renal function after adult deceased donor liver transplantation
, 2021 Jaehun Yang +10 more
openalex +2 more sources
Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients
Clinical Transplantation, Volume 40, Issue 2, February 2026.ABSTRACT Background and Aims Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan.
Emilie Høegholm Ernst Lauridsen +7 more
wiley +1 more source
Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A [PDF]
Dan Huang +9 more
openalex +1 more source